Government backed Israeli Syqe Medical Ltd. has developed a meter dosed marijuana inhaler that will allow patients to benefit from the benefits of cannabis, without the risk of getting high
Though medical marijuana’s entrance into the pharmaceutical market has allowed for great advances in patient care, the ability to manage the side effects of getting ‘high’ has eluded medical professionals. Until now, dosing was somewhat hit or miss. This can be problematic for patients who have never used marijuana before, as it can leave them unable to function properly when exposed to the drug.
Thanks to Syqe Medical’s new inhaler, patients may soon be able to have pre-measured doses of marijuana that allow them to take advantage of the benefits of cannabis, without an inhibiting high as a side effect. This could be a real game changer in Israel’s growing medicinal marijuana industry, which currently has 20,000 publicly sanctioned users.
“We may finally have a delivery system for medical cannabis that is effective, stable, safe, and easy to use,” said a reviewer at the Journal of Pain & Palliative Care Pharmacotherapy.
Not only will the inhaler boast precise dosing abilities, but will feature real time thermal control, flow control, and wireless connectivity, among other things. The Syqe Inhaler is set to be available for hospital use later this year, and will be hitting the home use market sometime in 2015.
How it works
Rather than using the traditional cannabis buds, the Syqe inhaler uses specially produced cannabis granules. They are loaded into the palm sized inhaler via a round cartridge that holds the granules. This allows for more accurate dosages, as the inhaler vaporizes the tiny granules of cannabis in doses that can be as small as 1 milligram. The form of cannabis used for these inhalers is also much harder to sell on the black market for profit.
“We are directly manipulating the human psyche in a very precise manner,” said Syqe Medical founder and chief executive Perry Davidson. “A physician could prescribe a custom-tailored, individualized treatment for that patient, and not have a hit or a miss, but [rather] a very close hit on the accurate dosing that the patient required.”
Mr. Davidson says that Israeli health officials are looking to bring the inhalers into local hospitals for pilot testing. Prior to the device’s debut in hospitals, Syqe hopes to raise $10-$15M from investors, some of which are based in the U.S.
“[The inhaler is] a pharmaceutical method for cannabis dosing, adding a much needed treatment in the limited armamentarium of effective therapies for the management of chronic pain,” wrote Elon Eisenberg, director of the Pain Unit at Haifa’s Rambam Hospital, in an Israeli clinical study on the inhaler that was published in the Journal of Pain and Palliative Care Pharmacology.
Syqe believes that the U.S. will be its main market in the future, as it cited research which predicts the medical marijuana market in the U.S. will grow by eight times to reach $10 billion in the next five years.